Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Original Article

T. Facon, S. Kumar, T. Plesner, R.Z. Orlowski, P. Moreau, N. Bahlis, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C.P. Venner, K. Weisel, J.R. Mace, N. Raje, M. Attal, M. Tiab, M. Macro, L. Frenzel, X. Leleu, T. Ahmadi, C. Chiu, J. Wang, R.V. Rampelbergh, C.M. Uhlar, R. Kobos, M. Qi, and S.Z. Usmani

N Engl J Med 2019;380:2104-2115

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
05/29/2019
Course expires: 
05/30/2021

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, May 30, 2021 - 11:59pm.